-VANDAAM study findings confirm test predicts aggressive prostate cancer in African American men – 

San Francisco, CA (UroToday.com) — Veracyte, Inc. announced new data from two studies that further demonstrate the Decipher® Prostate Genomic Classifier (GC) provides prognostic information that can help physicians tailor treatment decisions for men with prostate cancer. The findings will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held virtually June 4-8, 2021.